Restricted accessResearch articleFirst published online 2022-11
Type 2 Diabetes Mellitus Promotes the Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells into Cancer-Associated Fibroblasts,Induced by Breast Cancer Cells
Triple-negative breast cancer (TNBC) is a highly aggressive and invasive type of breast cancer. In addition, type 2 diabetes mellitus (T2DM) is recognized as a risk factor for cancer metastasis, which is associated with mortality in patients with breast cancer. Cancer-associated fibroblasts (CAFs) generated from adipose tissue-derived mesenchymal stem cells (AT-MSCs) play a vital role in the progression of TNBC. However, to date, whether T2DM affects the ability of AT-MSCs to differentiate into CAFs is still unclear. In this study, we found that in coculture with TNBC cells [breast cancer cells (BCCs)] under hypoxic conditions, AT-MSCs derived from T2DM donors (dAT-MSCs) were facilitated to differentiate into CAFs, which showed fibroblastic morphology and the induced expression of fibroblastic markers, such as fibroblast activation protein, fibroblast-specific protein, and vimentin. This was involved in the higher expression of transforming growth factor beta receptor 2 (TGFβR2) and the phosphorylation of Smad2/3. Furthermore, T2DM affected the fate and functions of CAFs derived from dAT-MSCs. While CAFs derived from AT-MSCs of healthy donors (AT-CAFs) exhibited the markers of inflammatory CAFs, those derived from dAT-MSCs (dAT-CAFs) showed the markers of myofibroblastic CAFs. Of note, in comparison with AT-CAFs, dAT-CAFs showed a higher ability to induce the proliferation and in vivo metastasis of BCCs, which was involved in the activation of the transforming growth factor beta (TGFβ)-Smad2/3 signaling pathway. Collectively, our study suggests that T2DM contributes to metastasis of BCCs by inducing the myofibroblastic CAFs differentiation of dAT-MSCs. In addition, targeting the TGFβ-Smad2/3 signaling pathway in dAT-MSCs may be useful in cancer therapy for TNBC patients with T2DM.
Get full access to this article
View all access options for this article.
References
1.
SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA and BrayF. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71:209–249.
2.
YinL, DuanJJ, BianXW and YuSC. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 22:61.
3.
Al-MahmoodS, SapiezynskiJ, GarbuzenkoOB and MinkoT. (2018). Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res, 8:1483–1507.
4.
MaishiN and HidaK. (2017). Tumor endothelial cells accelerate tumor metastasis. Cancer Sci, 108:1921–1926.
5.
RoyI, McAllisterDM, GorseE, DixonK, PiperCT, ZimmermanNP, GetschmanAE, TsaiS, EngleDD, et al. (2015). Pancreatic cancer cell migration and metastasis is regulated by chemokine-biased agonism and bioenergetic signaling. Cancer Res, 75:3529–3542.
6.
QuailDF and JoyceJA. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat Med, 19:1423–1437.
7.
SahaiE, AstsaturovI, CukiermanE, DeNardoDG, EgebladM, EvansRM, FearonD, GretenFR, HingoraniSR, et al. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer, 20:174–186.
8.
YuY, XiaoCH, TanLD, WangQS, LiXQ and FengYM. (2014). Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer, 110:724–732.
9.
JoshiRS, KanugulaSS, SudhirS, PereiraMP, JainS and AghiMK. (2021). The role of cancer-associated fibroblasts in tumor progression. Cancers (Basel), 13:1–27.
10.
BarrettRL and PureE. (2020). Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife, 9:e57243.
11.
DengL, JiangN, ZengJ, WangY and CuiH. (2021). The versatile roles of cancer-associated fibroblasts in colorectal cancer and therapeutic implications. Front Cell Dev Biol, 9:733270.
12.
SunamiY, HäußlerJ and KleeJ. (2020). Cellular heterogeneity of pancreatic stellate cells, mesenchymal stem cells, and cancer-associated fibroblasts in pancreatic cancer. Cancers (Basel), 12:1–15.
13.
BeckerLM, O'ConnellJT, VoAP, CainMP, TampeD, BizarroL, SugimotoH, McGowAK, AsaraJM, et al. (2020). Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep, 31:107701.
14.
MelissariMT, ChalkidiN, SarrisME and KoliarakiV. (2020). Fibroblast Reprogramming in Gastrointestinal Cancer. Front Cell Dev Biol, 8:630.
15.
Emami NejadA, NajafgholianS, RostamiA, SistaniA, ShojaeifarS, EsparvarinhaM, NedaeiniaR, Haghjooy JavanmardS, TaherianM, et al. (2021). The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int, 21:62.
16.
PetrovaV, Annicchiarico-PetruzzelliM, MelinoG and AmelioI. (2018). The hypoxic tumour microenvironment. Oncogenesis, 7:10.
17.
KarnoubAE, DashAB, VoAP, SullivanA, BrooksMW, BellGW, RichardsonAL, PolyakK, TuboR and WeinbergRA. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449:557–563.
18.
WuS, WangY, YuanZ, WangS, DuH, LiuX, WangQ and ZhuX. (2019). Human adipose-derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial-mesenchymal transition by cross interacting with the TGF-β/Smad and PI3K/AKT signaling pathways. Mol Med Rep, 19:177–186.
19.
ChenY, HeY, WangX, LuF and GaoJ. (2019). Adipose-derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells. Oncol Rep, 41:2126–2136.
20.
ChanTS, ShakedY and TsaiKK. (2019). Targeting the interplay between cancer fibroblasts, mesenchymal stem cells, and cancer stem cells in desmoplastic cancers. Front Oncol, 9:688.
21.
Barcellos-de-SouzaP, ComitoG, Pons-SeguraC, TaddeiML, GoriV, BecherucciV, BambiF, MargheriF, LaurenzanaA, Del RossoM and ChiarugiP. (2016). Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem Cells, 34:2536–2547.
22.
AltE, WelteG, LiJ, HennessyBT, DevarajanE, KrishnappaS, PinillaS, DrollL and JotzuC. (2010). Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol, 33:61–79.
23.
ZhangF, de Haan-DuJ, SidorenkovG, LandmanGWD, JalvingM, ZhangQ and de BockGH. (2021). Type 2 diabetes mellitus and clinicopathological tumor characteristics in women diagnosed with breast cancer: a systematic review and meta-analysis. Cancers (Basel), 13:4992.
24.
KhanhVC, FukushigeM, MoriguchiK, YamashitaT, OsakaM, HiramatsuY and OhnedaO. (2020). Type 2 diabetes mellitus induced paracrine effects on breast cancer metastasis through extracellular vesicles derived from human mesenchymal stem cells. Stem Cells Dev, 29:1382–1394.
25.
JakicB, BuszkoM, CappellanoG and WickG. (2017). Elevated sodium leads to the increased expression of HSP60 and induces apoptosis in HUVECs. PLoS One, 12:e0179383.
26.
SchmittgenTD and LivakKJ. (2008). Analyzing real-time PCR data by the comparative CT method. Nat Protoc, 3:1101–1108.
27.
NaganoM, YamashitaT, HamadaH, OhnedaK, KimuraK, NakagawaT, ShibuyaM, YoshikawaH and OhnedaO. (2007). Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood, 110:151–160.
28.
HanC, LiuT and YinR. (2020). Biomarkers for cancer-associated fibroblasts. Biomark Res, 8:64.
29.
MishraPJ, MishraPJ, HumeniukR, MedinaDJ, AlexeG, MesirovJP, GanesanS, GlodJW and BanerjeeD. (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res, 68:4331–4339.
30.
ChetehEH, SarneV, CederS, BianchiJ, AugstenM, RundqvistH, EgevadL, A Östman and WimanKG. (2020). Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov, 6:42.
31.
PingQ, YanR, ChengX, WangW, ZhongY, HouZ, ShiY, WangC and LiR. (2021). Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther, 28:984–999.
32.
TrinhNT, YamashitaT, OhnedaK, KimuraK, SalazarGTA, SatoF and OhnedaO. (2016). Increased expression of EGR-1 in diabetic human adipose tissue-derived mesenchymal stem cells reduces their wound healing capacity. Stem Cells Dev, 25:760–773.
33.
ShangguanL, TiX, KrauseU, HaiB, ZhaoY, YangZ and LiuF. (2012). Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells, 30:2810–2819.
34.
ChenJ, JiT, WuD, JiangS, ZhaoJ, CaiX and LinH. (2019). Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma. Cell Death Dis, 10:425.
35.
D'EspositoV, AmbrosioMR, GiulianoM, CabaroS, MieleC, BeguinotF and FormisanoP. (2020). Mammary adipose tissue control of breast cancer progression: impact of obesity and diabetes. Front Oncol, 10:1554.
36.
ZhaoM, SachsPC, WangX, DumurCI, IdowuMO, RobilaV, FrancisMP, WareJ, BeckmanM, et al. (2012). Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther, 13:782–792.
37.
ChenB, SangY, SongX, ZhangD, WangL, ZhaoW, LiangY, ZhangN and YangQ. (2021). Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. Theranostics, 11:3932–3947.
38.
PaunescuV, BojinFM, TatuCA, GavriliucOI, RoscaA, GruiaAT, TanasieG, BunuC, CrisnicD, et al. (2011). Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med, 15:635–646.
39.
KalluriR. (2016). The biology and function of fibroblasts in cancer. Nat Rev Cancer, 16:582–598.
40.
MiyazakiY, OdaT, MoriN and KidaYS. (2020). Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro. FEBS Open Bio, 10:2268–2281.
41.
MonteranL and ErezN. (2019). The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol, 10:1835.
42.
NurmikM, UllmannP, RodriguezF, HaanS and LetellierE. (2020). In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer, 146:895–905.
43.
RahmanI, AtharMT and IslamM. (2021). Type 2 diabetes, obesity, and cancer share some common and critical pathways. Front Oncol, 10:600824.
44.
LeeKN, TorresMA, TroeschelAN, HeJ, GogineniK and McCulloughLE. (2020). Type 2 diabetes, breast cancer specific and overall mortality: associations by metformin use and modification by race, body mass, and estrogen receptor status. PLoS One, 15:e0232581.
45.
Eketunde AO. (2020). Diabetes as a risk factor for breast cancer. Cureus, 12:e8010.
46.
HardefeldtPJ, EdirimanneS and EslickGD. (2012). Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer, 19:793–803.
47.
XueF and MichelsKB. (2007). Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr, 86:s823–s835.
48.
ÖhlundD, Handly-SantanaA, BiffiG, ElyadaE, AlmeidaAS, Ponz-SarviseM, CorboV, OniTE, HearnSA, et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med, 214:579–596.
49.
CaseyTM, EnemanJ, CrockerA, WhiteJ, TessitoreJ, StanleyM, HarlowS, BunnJY, WeaverD, MussH and PlautK. (2008). Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat, 110:39–49.
50.
MaX, CuiZ, DuZ and LinH. (2020). Transforming growth factor-β signaling, a potential mechanism associated with diabetes mellitus and pancreatic cancer?. J Cell Physiol, 235:5882–5892.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
